ZA200602070B - Matrix metalloproteinase inhibitors - Google Patents

Matrix metalloproteinase inhibitors Download PDF

Info

Publication number: ZA200602070B
Authority: ZA; South Africa
Prior art keywords: formula; compound; alkyl; cor; bond
Prior art date: 2003-09-13

Application number

ZA200602070A

Other languages

English (en)

Inventor

Gaines Simon

Martin Stephen Lewis

Holmes Ian Peter

Watson Stephen Paul

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-13

Filing date

2006-03-10

Publication date

2007-05-30

2006-03-10 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2007-05-30 Publication of ZA200602070B publication Critical patent/ZA200602070B/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Anti-Oxidant Or Stabilizer Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Macromonomer-Based Addition Polymer (AREA)
Indole Compounds (AREA)
Soft Magnetic Materials (AREA)
Adhesives Or Adhesive Processes (AREA)
Lubricants (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA200602070A 2003-09-13 2006-03-10 Matrix metalloproteinase inhibitors ZA200602070B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0321538.1A GB0321538D0 (en)	2003-09-13	2003-09-13	Therapeutically useful compounds

Publications (1)

Publication Number	Publication Date
ZA200602070B true ZA200602070B (en)	2007-05-30

Family

ID=29227079

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200602070A ZA200602070B (en)	2003-09-13	2006-03-10	Matrix metalloproteinase inhibitors

Country Status (28)

Country	Link
US (3)	US7601729B2 (de)
EP (3)	EP2042488B1 (de)
JP (3)	JP2007505081A (de)
KR (3)	KR20130079628A (de)
CN (1)	CN1849306B (de)
AT (2)	ATE413384T1 (de)
AU (1)	AU2004272280C1 (de)
BR (1)	BRPI0413791A (de)
CA (1)	CA2538315C (de)
CY (1)	CY1109400T1 (de)
DE (2)	DE602004017622D1 (de)
DK (1)	DK1663970T3 (de)
ES (2)	ES2362954T3 (de)
GB (1)	GB0321538D0 (de)
HR (1)	HRP20080668T3 (de)
IL (1)	IL173305A (de)
IS (2)	IS2622B (de)
MA (1)	MA28039A1 (de)
MX (1)	MXPA06002458A (de)
NO (1)	NO20060540L (de)
NZ (2)	NZ573479A (de)
PL (1)	PL1663970T3 (de)
PT (1)	PT1663970E (de)
RU (2)	RU2370488C2 (de)
SG (1)	SG145685A1 (de)
SI (1)	SI1663970T1 (de)
WO (1)	WO2005026120A1 (de)
ZA (1)	ZA200602070B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0321538D0 (en) *	2003-09-13	2003-10-15	Glaxo Group Ltd	Therapeutically useful compounds
KR101274309B1 (ko) *	2005-02-22	2013-06-13	랜박시 래보러터리스 리미티드	천식 및 기타 질병의 치료를 위한 기질 메탈로프로테나제저해제로서 5-페닐-펜탄산 유도체
BRPI0715231A2 (pt)	2006-08-22	2013-06-25	Ranbaxy Lab Ltd	compostos, composiÇÕes farmacÊuticas e seus usos, auxiliar quiral e seu uso e processos para preparar um composto
AU2013200728B2 (en) *	2006-08-22	2014-12-18	Sun Pharmaceutical Industries Limited	Matrix metalloproteinase inhibitors
CA2963784A1 (en)	2007-06-08	2008-12-18	Mannkind Corporation	Ire-1.alpha. inhibitors
FR2949463B1 (fr) *	2009-08-26	2011-09-16	Commissariat Energie Atomique	Inhibiteurs de mmp
KR20130042590A (ko)	2010-07-30	2013-04-26	랜박시 래보러터리스 리미티드	기질 메탈로프로테나제 저해제
CN103228634A (zh)	2010-09-24	2013-07-31	兰贝克赛实验室有限公司	基质金属蛋白酶抑制剂
WO2014083229A1 (es)	2012-11-28	2014-06-05	Administración General De La Comunidad Autónoma De Euskadi	Uso de inhibidores de metaloproteasas en el tratamiento de enfermedades hepáticas poliquísticas
LT3413892T (lt)	2016-02-12	2022-06-10	Cytokinetics, Incorporated	Tetrahidroizochinolino dariniai
CN110769866B (zh) *	2017-06-13	2022-07-29	爱惜康有限责任公司	具有可控愈合的外科缝合器

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4102024A1 (de) *	1991-01-24	1992-07-30	Thomae Gmbh Dr K	Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU2199195A (en) *	1994-04-28	1995-11-29	Uniroyal Chemical Company, Inc.	Fungicidal azole derivatives
NZ323521A (en) *	1995-12-06	1999-10-28	Astra Pharma Prod	Compounds for treating reversible obstructive airway disease or allergic conditions
EP0898566B1 (de)	1996-04-19	2002-11-06	Akzo Nobel N.V.	Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
TNSN97085A1 (fr) *	1996-05-15	2005-03-15	Bayer Corp	Substitution oxybuterique des acides comme inhibiteurs de la matrice metalloprotease
US5789605A (en)	1996-12-03	1998-08-04	Trustees Of The University Of Pennsylvania	Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof
US6096904A (en)	1996-12-03	2000-08-01	The Trustees Of The University Of Pennsylvania	Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US6870058B2 (en)	1996-12-03	2005-03-22	The Trustees Of The University Of Pennsylvania	Compounds which mimic the chemical and biological properties of discodermolide
US6242616B1 (en)	1996-12-03	2001-06-05	The Trustees Of The University Of Pennsylvania	Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US20050065353A1 (en)	1996-12-03	2005-03-24	Smith Amos B.	Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
US5804581A (en) *	1997-05-15	1998-09-08	Bayer Corporation	Inhibition of matrix metalloproteases by substituted phenalkyl compounds
US6608052B2 (en) *	2000-02-16	2003-08-19	Boehringer Ingelheim Pharmaceuticals, Inc.	Compounds useful as anti-inflammatory agents
MXPA03009361A (es) *	2001-04-13	2004-01-29	Boehringer Ingelheim Pharma	Compuestos de urea utilies como agentes anti-inflamatorios.
WO2004012663A2 (en)	2002-08-01	2004-02-12	Bristol-Myers Squibb Company	Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
WO2004046091A2 (en) *	2002-11-19	2004-06-03	Galderma Research & Development, S.N.C.	Biaromatic compounds which activate ppar-gama type receptors, and use thereof in cosmetic or pharmaceutical compositions
GB0312654D0 (en) *	2003-06-03	2003-07-09	Glaxo Group Ltd	Therapeutically useful compounds
GB0314488D0 (en) *	2003-06-20	2003-07-23	Glaxo Group Ltd	Therapeutically useful compounds
GB0319069D0 (en) *	2003-08-14	2003-09-17	Glaxo Group Ltd	Therapeutically useful compounds
GB0321538D0 (en) *	2003-09-13	2003-10-15	Glaxo Group Ltd	Therapeutically useful compounds
KR101274309B1 (ko)	2005-02-22	2013-06-13	랜박시 래보러터리스 리미티드	천식 및 기타 질병의 치료를 위한 기질 메탈로프로테나제저해제로서 5-페닐-펜탄산 유도체
BRPI0715231A2 (pt)	2006-08-22	2013-06-25	Ranbaxy Lab Ltd	compostos, composiÇÕes farmacÊuticas e seus usos, auxiliar quiral e seu uso e processos para preparar um composto

2003
- 2003-09-13 GB GBGB0321538.1A patent/GB0321538D0/en not_active Ceased
2004
- 2004-09-10 CN CN200480026229.7A patent/CN1849306B/zh not_active Expired - Fee Related
- 2004-09-10 RU RU2006106850/04A patent/RU2370488C2/ru not_active IP Right Cessation
- 2004-09-10 EP EP08163972A patent/EP2042488B1/de not_active Expired - Lifetime
- 2004-09-10 BR BRPI0413791-4A patent/BRPI0413791A/pt not_active IP Right Cessation
- 2004-09-10 ES ES08163972T patent/ES2362954T3/es not_active Expired - Lifetime
- 2004-09-10 US US10/571,443 patent/US7601729B2/en not_active Expired - Fee Related
- 2004-09-10 AT AT04765231T patent/ATE413384T1/de active
- 2004-09-10 HR HR20080668T patent/HRP20080668T3/xx unknown
- 2004-09-10 DE DE602004017622T patent/DE602004017622D1/de not_active Expired - Lifetime
- 2004-09-10 CA CA2538315A patent/CA2538315C/en not_active Expired - Fee Related
- 2004-09-10 PT PT04765231T patent/PT1663970E/pt unknown
- 2004-09-10 NZ NZ573479A patent/NZ573479A/en not_active IP Right Cessation
- 2004-09-10 SI SI200431008T patent/SI1663970T1/sl unknown
- 2004-09-10 MX MXPA06002458A patent/MXPA06002458A/es active IP Right Grant
- 2004-09-10 EP EP10176905A patent/EP2295408A1/de not_active Withdrawn
- 2004-09-10 KR KR1020137014317A patent/KR20130079628A/ko not_active Ceased
- 2004-09-10 PL PL04765231T patent/PL1663970T3/pl unknown
- 2004-09-10 ES ES04765231T patent/ES2314436T3/es not_active Expired - Lifetime
- 2004-09-10 AT AT08163972T patent/ATE502922T1/de not_active IP Right Cessation
- 2004-09-10 DE DE602004031991T patent/DE602004031991D1/de not_active Expired - Lifetime
- 2004-09-10 WO PCT/EP2004/010319 patent/WO2005026120A1/en not_active Ceased
- 2004-09-10 JP JP2006525794A patent/JP2007505081A/ja active Pending
- 2004-09-10 KR KR1020067005114A patent/KR20060120648A/ko not_active Ceased
- 2004-09-10 NZ NZ545211A patent/NZ545211A/en not_active IP Right Cessation
- 2004-09-10 SG SG200805432-2A patent/SG145685A1/en unknown
- 2004-09-10 AU AU2004272280A patent/AU2004272280C1/en not_active Ceased
- 2004-09-10 EP EP04765231A patent/EP1663970B1/de not_active Expired - Lifetime
- 2004-09-10 DK DK04765231T patent/DK1663970T3/da active
- 2004-09-10 KR KR1020127000264A patent/KR20120007566A/ko not_active Ceased
2006
- 2006-01-23 IL IL173305A patent/IL173305A/en not_active IP Right Cessation
- 2006-01-26 IS IS8268A patent/IS2622B/is unknown
- 2006-02-02 NO NO20060540A patent/NO20060540L/no not_active Application Discontinuation
- 2006-03-10 ZA ZA200602070A patent/ZA200602070B/en unknown
- 2006-03-14 MA MA28873A patent/MA28039A1/fr unknown
2008
- 2008-11-07 US US12/266,767 patent/US8263602B2/en not_active Expired - Fee Related
- 2008-11-26 RU RU2008146479/04A patent/RU2008146479A/ru not_active Application Discontinuation
2009
- 2009-01-27 CY CY20091100090T patent/CY1109400T1/el unknown
- 2009-08-19 IS IS8843A patent/IS8843A/is unknown
- 2009-09-01 US US12/551,892 patent/US8343986B2/en not_active Expired - Fee Related
2011
- 2011-06-14 JP JP2011132261A patent/JP2011231118A/ja not_active Withdrawn
2012
- 2012-01-25 JP JP2012012663A patent/JP2012107031A/ja active Pending

Also Published As

Publication number	Publication date
CY1109400T1 (el)	2014-07-02
DE602004031991D1 (de)	2011-05-05
KR20120007566A (ko)	2012-01-20
KR20060120648A (ko)	2006-11-27
GB0321538D0 (en)	2003-10-15
EP2042488A1 (de)	2009-04-01
US20090082377A1 (en)	2009-03-26
US20100029699A1 (en)	2010-02-04
MA28039A1 (fr)	2006-07-03
JP2011231118A (ja)	2011-11-17
IS8268A (is)	2006-01-26
CA2538315C (en)	2014-04-08
NO20060540L (no)	2006-04-04
PT1663970E (pt)	2009-01-09
DK1663970T3 (da)	2009-01-12
CN1849306A (zh)	2006-10-18
NZ573479A (en)	2010-09-30
US20060293353A1 (en)	2006-12-28
KR20130079628A (ko)	2013-07-10
US8343986B2 (en)	2013-01-01
SI1663970T1 (sl)	2009-04-30
IS8843A (is)	2009-08-19
RU2006106850A (ru)	2007-10-20
ES2362954T3 (es)	2011-07-15
EP1663970A1 (de)	2006-06-07
IL173305A (en)	2011-01-31
AU2004272280C1 (en)	2011-10-27
EP2295408A1 (de)	2011-03-16
EP1663970B1 (de)	2008-11-05
IS2622B (is)	2010-05-15
BRPI0413791A (pt)	2006-11-07
CN1849306B (zh)	2014-01-29
CA2538315A1 (en)	2005-03-24
ATE413384T1 (de)	2008-11-15
RU2008146479A (ru)	2010-06-20
HK1092141A1 (en)	2007-02-02
JP2012107031A (ja)	2012-06-07
MXPA06002458A (es)	2006-06-20
NZ545211A (en)	2009-01-31
ATE502922T1 (de)	2011-04-15
ES2314436T3 (es)	2009-03-16
RU2370488C2 (ru)	2009-10-20
AU2004272280A1 (en)	2005-03-24
US7601729B2 (en)	2009-10-13
IL173305A0 (en)	2006-06-11
DE602004017622D1 (de)	2008-12-18
HRP20080668T3 (hr)	2009-02-28
WO2005026120A1 (en)	2005-03-24
PL1663970T3 (pl)	2009-04-30
US8263602B2 (en)	2012-09-11
EP2042488B1 (de)	2011-03-23
AU2004272280B2 (en)	2011-04-21
SG145685A1 (en)	2008-09-29
JP2007505081A (ja)	2007-03-08

Publication	Publication Date	Title
US7250514B1 (en)	2007-07-31	Histone deacetylase inhibitors
US7154002B1 (en)	2006-12-26	Histone deacetylase inhibitors
ES2353020T3 (es)	2011-02-24	(piridinil)alquil-amidas o -ureas como inhibidores de la producción del tnf-alfa.
US4336381A (en)	1982-06-22	5-Fluorouracil derivatives
EP1176956B1 (de)	2008-01-09	Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
AU2002214947B2 (en)	2007-02-15	Cyanoguanidine prodrugs
AU778819B2 (en)	2004-12-23	5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
KR20020084088A (ko)	2002-11-04	히드록시피콜린산 유도체의 제조 방법
EP1189881B2 (de)	2013-01-23	Propansäurederivate, die die bindung von integrinen an ihre rezeptoren behindern
US6100273A (en)	2000-08-08	Water soluble camptothecin derivatives
PL192864B1 (pl)	2006-12-29	Pochodna pirazyny i środek farmaceutyczny
BG62329B1 (bg)	1999-08-31	Оптично активни фунгицидни производни на 2-имидазолин-5-они/тиони
HUP0202501A2 (hu)	2002-12-28	Pirimidin-2,4,6-trion metalloproteináz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HU208811B (en)	1994-01-28	Process for producton of biaryl-compounds and pharmaceutical compositions comprising them as medical agent
EP3277662B1 (de)	2025-01-22	Schwefelwasserstoffvorläufer und deren konjugate
HU205917B (en)	1992-07-28	Process for producing 6-substituted pyrimidine derivatives and antiviral pharmaceutical compositions containing them as active components
US4259344A (en)	1981-03-31	Sulfur-containing benzimidazole derivatives
EP1103543A1 (de)	2001-05-30	Harnstoffderivate mit stickstoffhaltigen aromatischen heterocyclen
CA2538315C (en)	2014-04-08	Matrix metalloproteinase inhibitors
US4279899A (en)	1981-07-21	Benzylpyrimidines, processes for their manufacture, and drugs containing the said compounds
CA2473763A1 (en)	2003-07-31	Compounds for modulating cell proliferation
SK5082002A3 (en)	2002-10-08	Beta disubstituted metalloprotease inhibitors
US6593323B1 (en)	2003-07-15	Benzimidazole compounds and drugs containing the same
EP0404949A1 (de)	1991-01-02	Substituierte acetamid-derivate, verfahren zur herstellung und antigeschwulstheilmittel, das diese enthalten
MC1222A1 (fr)	1979-07-20	Nouvelles 2,4-diamino-5-benzylpyrimidines,leur preparation et leur application en tant que medicaments